Add to my selection

HALAVEN

Medicine - Posted on Nov 30 2018 - Updated on Jun 12 2019

Active substance (DCI)

éribuline (mésilate de)

history (4)

11/21/18

HALAVEN (éribuline), antinéoplasique

Intérêt clinique important dans le cancer du sein, avancé ou métastatique, mais pas d’avantage clinique démontré par rapport...

CAV :
54321

icône flèche
5/3/17

HALAVEN (eribulin), antineoplastic agent

Moderate clinical added value relative to dacarbazine as a monotherapy in advanced or metastatic unresectable liposarcoma in...

CAV :
54321

icône flèche
9/23/15

HALAVEN (eribulin), antineoplastic agent

No clinical benefit demonstrated in the second-line treatment of locally advanced or metastatic breast cancer in patients in...

CAV :
54321

icône flèche
7/20/11

HALAVEN

-

CAV :
54321

icône flèche

Technical information

ATC code

L01XX41

Manufacturer

EISAI SAS

Presentation

HALAVEN 0,44 mg/ml, solution injectable (code CIS : 63816522) : 1 flacon(s) en verre de 2 ml - Code CIP : 3400941835230 / 6 flacon(s) en verre de 2 ml - Code CIP : 3400941835469

All our publications

Breast cancers

Drug therapy

Health economics

Skin and connective tissue cancers

My account

You do not have a saved search

No element in selection

HALAVEN

HALAVEN (éribuline), antinéoplasique

HALAVEN (eribulin), antineoplastic agent

HALAVEN (eribulin), antineoplastic agent

HALAVEN

Follow us :